What is the Role of Real-World Data in Metastatic Renal Cell Cancer?

References

• Chin AI , LamJS, FiglinRA, BelldegrunAS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol.8(1), 1–7 (2006).
   PubMedGoogle Scholar
• Cancer Research UK . Kidney cancer statistics (2021). www.cancerresearchuk.org/health-professional/kidney-cancer-diagnosis-statistics#heading-Two
   Google Scholar
• Escudier B , PortaC, SchmidingerMet al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.30(5), 706–720 (2019).
   PubMed Web of Science ®Google Scholar
• Clark PE . The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int.76(9), 939–945 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , HutsonTE, TomczakPet al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol.27(22), 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , EscudierB, McDermottDFet al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.373(19), 1803–1813 (2015).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , PenkovK, HaanenJet al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.380(12), 1103–1115 (2019).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , TannirNM, McDermottDFet al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med.378(14), 1277–1290 (2018).
   PubMed Web of Science ®Google Scholar
• Rini BI , PlimackER, StusVet al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.380(12), 1116–1127 (2019).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , HutsonTE, GlenHet al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol.16(15), 1473–1482 (2015).
   PubMed Web of Science ®Google Scholar
• Motzer R , AlekseevB, RhaSYet al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med.384(14), 1289–1300 (2021).
   PubMed Web of Science ®Google Scholar
• Ravaud A , MotzerRJ, PandhaHSet al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med.375(23), 2246–2254 (2016).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , TomczakP, ParkSHet al. Pembrolizumab vs placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: randomized, double-blind, phase 3 KEYNOTE-564 study. J. Clin. Oncol.39(Suppl. 15), LBA5 (2021).
   Google Scholar
• Motzer RJ , MazumdarM, BacikJet al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17(8), 2530–2540 (1999).
   PubMed Web of Science ®Google Scholar
• Heng DY , XieW, ReganMMet al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol.27(34), 5794–9 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , BanchereauR, HamidiHet al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell.38(6), 803–817.e4 (2020).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , RiniBI, McDermottDFet al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol.20(10), 1370–1385 (2019).
   PubMed Web of Science ®Google Scholar
• Wong HH , SieglerC, GraingerSet al. Improving clinical trial recruitment: experience of a tertiary renal oncology centre. Oncology.85(5), 297–298 (2013).
   PubMed Web of Science ®Google Scholar
• Colomba E , LeTeuff G, EisenTet al. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: a Renal Cross Channel Group study. Eur J Cancer.80, 55–62 (2017).
   PubMed Web of Science ®Google Scholar
• Gravis G , ChanezB, DerosaLet al. Renal Cross Channel Group. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urol. Oncol.34(4), 167.e17–23 (2016).
   PubMed Web of Science ®Google Scholar
• Shuch B , LaRochelle JC, KlatteTet al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer.113(7), 1641–1648 (2008).
   PubMed Web of Science ®Google Scholar
• Moran M , NickensD, AdcockKet al. Sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world and clinical trials data. Target Oncol.14(4), 405–416 (2019).
   PubMed Web of Science ®Google Scholar
• Moran M , NickensD, AdcockKet al. Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: a systematic review and meta-analysis. Future Oncol.15(34), 3987–4001 (2019).
   PubMed Web of Science ®Google Scholar
• Rini B , DorffTB, ElsonPet al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol.17(9), 1317–1324 (2016).
   PubMed Web of Science ®Google Scholar
• Berghen C , JoniauS, VulstekeCet al. Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. Ecancermedicalscience.14, 1036 (2020).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , HalabiS, SanfordBLet al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol.35(6), 591–597 (2017).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , PowlesT, BurottoMet al. 696O_PR Nivolumab+cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. Ann. Oncol.31(Suppl. 4), S1142–S1215 (2020).
   Google Scholar
• Lee CH , ShahAY, RascoDet al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol.22(7), 946–958 (2021).
   PubMed Web of Science ®Google Scholar
• Stukalin I , WellsC, FracconAPet al. Fourth-line therapy in metastatic renal cell carcinoma (mRCC): results from the International mRCC Database Consortium (IMDC). J. Clin. Oncol.35(Suppl. 6), 498–498 (2017).
   PubMed Web of Science ®Google Scholar